PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1067.86%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
39.05%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
24.67%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
25.26%
EPS growth under 50% of CRVO's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
25.26%
Diluted EPS growth under 50% of CRVO's 100.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.67%
Negative OCF growth while CRVO is at 27.62%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-25.67%
Negative FCF growth while CRVO is at 28.53%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.29%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-10.29%
Negative 5Y OCF/share CAGR while CRVO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-46.03%
Negative 3Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
68.39%
10Y net income/share CAGR of 68.39% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
68.39%
Net income/share CAGR of 68.39% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
65.23%
3Y net income/share CAGR of 65.23% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-358.21%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-358.21%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-14.02%
Negative 3Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.24%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
8.21%
We have some new debt while CRVO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-39.30%
We cut SG&A while CRVO invests at 20.11%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.